Earnings Releases·Nov 4, 2026, 4:13 PM ET

Acadia Pharmaceuticals — Third Quarter 2026 Earnings Summary

GAAP total revenues reached $342 million in Q3 2026, a 23% increase year-over-year, driven by 14% growth in NUPLAZID sales to $202 million and a 39% surge in DAYBUE sales to $140 million; net income declined to $54 million ($0.31/share) from $72 million ($0.42/share) in Q3 2025.
Full-year 2026 revenue guidance was revised to $1.265–$1.295 billion, with DAYBUE guidance raised to $505–$520 million and R&D expense guidance lowered to $325–$340 million, while NUPLAZID guidance was narrowed to $760–$775 million.
Strategic milestones include the European launch of DAYBU (trofinetide) in Germany following EC approval, the receipt of FDA Fast Track designation for remlifanserin, and a new U.S. patent allowance extending protections for DAYBUE through March 2041.
The company maintains a strong liquidity position with $976 million in cash and investment securities as of September 30, 2026, and anticipates two Phase 2 readouts in 2027 for ACP-211 and remlifanserin.